The AO Foundation is a medically guided nonprofit organization led by an international group of surgeons specialized in the treatment of trauma and disorders of the musculoskeletal system. Founded in 1958 by 13 visionary surgeons, AO today fosters one of the most extensive networks of currently more than 10,000 surgeons, operating room personnel, and scientists in over 100 countries.
The AO Foundation is represented within the BALI consortium by two of its service units, the AO Research Institute Davos (ARI) and AO Clinical Investigation and Documentation (AOCID).
The mission of AO Research Institute Davos is excellence in research and development within trauma and disorders of the musculoskeletal system and translation of this knowledge to achieve more effective patient care worldwide.
The ARI work-package, headed by Fintan Moriarty ARI Group Leader of the musculoskeletal Infection group, will be responsible for the preclinical testing of the novel OP-145:Polypid coating using an intramedullary nail model in the rabbit, utilising the engineering and surgical expertise and track record of the ARI. The aim of the work is to determine the efficacy of the novel coating to both prevent and treat implant associated infections, prior to the clinical study.
The mission of AO Clinical Investigation and Documentation (AOCID) is to be the leading research organization providing evidence-based knowledge through independently conducted clinical studies, education, and methodological services, in order to facilitate clinical decision making in the field of trauma or musculoskeletal disorders.
The AOCID work-package, headed by Andreas Fäh, Clinical Operations Manager at AOCID, will be responsible for the performance of clinical trials, utilising the extensive network available to AOCID and the years of experience in performing such clinical trials in the field of orthopaedic surgery.